MX361369B - Modificaciones cristalinas estables de cloruro de dotap. - Google Patents
Modificaciones cristalinas estables de cloruro de dotap.Info
- Publication number
- MX361369B MX361369B MX2013013403A MX2013013403A MX361369B MX 361369 B MX361369 B MX 361369B MX 2013013403 A MX2013013403 A MX 2013013403A MX 2013013403 A MX2013013403 A MX 2013013403A MX 361369 B MX361369 B MX 361369B
- Authority
- MX
- Mexico
- Prior art keywords
- crystal modifications
- stable crystal
- dotap chloride
- preparation
- dotap
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
La presente invención se relaciona con modificaciones cristalinas del cloruro racémico de (2R, S)- y enantioméricamente puro (2R)- resp. (2S)-DOTAP, con los procesos para la preparación de estos, y con el uso de los mismos para la preparación de composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488428P | 2011-05-20 | 2011-05-20 | |
| PCT/EP2012/001882 WO2012159704A1 (en) | 2011-05-20 | 2012-05-02 | Stable crystal modifications of dotap chloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013403A MX2013013403A (es) | 2013-12-10 |
| MX361369B true MX361369B (es) | 2018-12-05 |
Family
ID=46044632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013403A MX361369B (es) | 2011-05-20 | 2012-05-02 | Modificaciones cristalinas estables de cloruro de dotap. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10000445B2 (es) |
| EP (1) | EP2709981B1 (es) |
| JP (3) | JP6290076B2 (es) |
| KR (1) | KR101974231B1 (es) |
| CN (2) | CN103547560A (es) |
| AU (1) | AU2012261276B2 (es) |
| BR (2) | BR112013029588B1 (es) |
| CA (1) | CA2836499C (es) |
| ES (1) | ES2726526T3 (es) |
| HK (1) | HK1251217A1 (es) |
| HU (1) | HUE042949T2 (es) |
| IL (1) | IL229146B (es) |
| MX (1) | MX361369B (es) |
| NO (1) | NO344225B1 (es) |
| PL (1) | PL2709981T3 (es) |
| PT (1) | PT2709981T (es) |
| RU (1) | RU2627354C2 (es) |
| SG (2) | SG10201706859QA (es) |
| TR (1) | TR201906107T4 (es) |
| WO (1) | WO2012159704A1 (es) |
| ZA (1) | ZA201309638B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2709981T (pt) * | 2011-05-20 | 2019-05-30 | Merck Patent Gmbh | Preparação de modificações cristalinas estáveis de cloreto de dotap |
| WO2016093205A1 (ja) * | 2014-12-08 | 2016-06-16 | 日油株式会社 | カチオン性脂質の製造方法 |
| CN107827762B (zh) * | 2017-11-14 | 2020-10-02 | 苏州东南药业股份有限公司 | 一种(2,3-二油酰基-丙基)三甲基氯化铵及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| DE4013632A1 (de) | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
| DE19521412A1 (de) * | 1995-06-14 | 1996-12-19 | Boehringer Mannheim Gmbh | Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung |
| US5869715A (en) | 1995-09-27 | 1999-02-09 | The Reagents Of The University Of California | Polyfunctional cationic cytofectins |
| US20030129223A1 (en) | 2000-10-11 | 2003-07-10 | Targesome, Inc. | Targeted multivalent macromolecules |
| AU2002953285A0 (en) * | 2002-12-12 | 2003-01-02 | Protech Research Pty Ltd | Yeast treatment |
| ITMI20032185A1 (it) * | 2003-11-12 | 2005-05-13 | Chemi Spa | Processo per la sintesi di lipidi cationici. |
| DE102004057303A1 (de) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
| PT2709981T (pt) * | 2011-05-20 | 2019-05-30 | Merck Patent Gmbh | Preparação de modificações cristalinas estáveis de cloreto de dotap |
-
2012
- 2012-05-02 PT PT12719274T patent/PT2709981T/pt unknown
- 2012-05-02 MX MX2013013403A patent/MX361369B/es active IP Right Grant
- 2012-05-02 RU RU2013156477A patent/RU2627354C2/ru active
- 2012-05-02 EP EP12719274.8A patent/EP2709981B1/en active Active
- 2012-05-02 CN CN201280024160.9A patent/CN103547560A/zh active Pending
- 2012-05-02 JP JP2014511756A patent/JP6290076B2/ja active Active
- 2012-05-02 BR BR112013029588-0A patent/BR112013029588B1/pt active IP Right Grant
- 2012-05-02 SG SG10201706859QA patent/SG10201706859QA/en unknown
- 2012-05-02 PL PL12719274T patent/PL2709981T3/pl unknown
- 2012-05-02 US US14/118,571 patent/US10000445B2/en active Active
- 2012-05-02 BR BR122021007641A patent/BR122021007641B8/pt active Search and Examination
- 2012-05-02 CN CN201810169562.7A patent/CN108285422A/zh active Pending
- 2012-05-02 WO PCT/EP2012/001882 patent/WO2012159704A1/en active Application Filing
- 2012-05-02 SG SG2013084363A patent/SG194957A1/en unknown
- 2012-05-02 CA CA2836499A patent/CA2836499C/en active Active
- 2012-05-02 AU AU2012261276A patent/AU2012261276B2/en active Active
- 2012-05-02 HU HUE12719274A patent/HUE042949T2/hu unknown
- 2012-05-02 TR TR2019/06107T patent/TR201906107T4/tr unknown
- 2012-05-02 ES ES12719274T patent/ES2726526T3/es active Active
- 2012-05-02 KR KR1020137034017A patent/KR101974231B1/ko active IP Right Grant
-
2013
- 2013-10-30 IL IL229146A patent/IL229146B/en active IP Right Grant
- 2013-12-18 NO NO20131703A patent/NO344225B1/no unknown
- 2013-12-19 ZA ZA2013/09638A patent/ZA201309638B/en unknown
-
2016
- 2016-12-02 JP JP2016234716A patent/JP2017075166A/ja active Pending
-
2018
- 2018-08-22 HK HK18110787.6A patent/HK1251217A1/zh unknown
- 2018-09-25 JP JP2018178658A patent/JP2018203776A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20150091A2 (ro) | Compuşi antivirali | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| IN2015KN00262A (es) | ||
| MY161088A (en) | Agonists of gpr40 | |
| UA109661C2 (uk) | Фармацевтична композиція співкристалів трамадолу і коксибів | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| NZ608116A (en) | Triazine-oxadiazoles | |
| GB201106743D0 (en) | Novel compounds | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| MX2013003309A (es) | Compuestos de benzamida sustituidos. | |
| MX2015004604A (es) | Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas. | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| JO3154B1 (ar) | عوامل مضادة لـ trpv4 | |
| EA033171B1 (ru) | Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол | |
| GEP201706621B (en) | Benzamides | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| MX362879B (es) | Usos novedosos. | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| MX2015003034A (es) | Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso. | |
| MX361369B (es) | Modificaciones cristalinas estables de cloruro de dotap. | |
| EA201391643A1 (ru) | Составы с замедленным высвобождением парацетамола | |
| MX2014004210A (es) | Derivados de 2-oxo-piperidinilo. | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |